Compounded semaglutide injection information with formulation-specific safety and clinician-review context.
Compounded · Not FDA-approvedCompounded medications are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Prepared by a state-licensed compounding pharmacy operating under Section 503A. Appropriateness and lawful availability require individual clinician and licensed-pharmacy review.
Subcutaneous injection
GLP-1 receptor agonist
Compounded by a licensed 503A pharmacy
Weight-management treatment may be considered for eligible adults following an individualized clinical review of medical need, alternatives, and whether a compounded injection is appropriate and lawfully available. Listing a treatment does not guarantee access.
Semaglutide activates GLP-1 receptors, influencing appetite, slowing gastric emptying, and supporting glucose-dependent insulin signaling. Mechanism alone does not establish efficacy for a compounded preparation.
Compounded semaglutide is prescribed only when a licensed provider determines it is clinically appropriate. Compounded medications are not FDA-approved.
Published studies provide ingredient-level context in specific populations. They are not clinical trials of this compounded medication and do not establish its potency, dosing, safety, efficacy, or outcomes. Individual results vary.
A treatment listing does not determine eligibility or guarantee a prescription.
Medical history, weight trajectory, treatment goals, current medications, pregnancy or breastfeeding, endocrine and gastrointestinal conditions, pancreatitis or gallbladder history, kidney function, and contraindications. Personal or family history of medullary thyroid carcinoma or MEN2 requires particular attention.
Nausea, vomiting, diarrhea, constipation, dehydration, kidney injury, gallbladder problems, and pancreatitis are important risks. Hypoglycemia can occur with insulin or certain diabetes medicines. Thyroid C-cell tumor warnings, pregnancy, severe gastrointestinal disease, and medication interactions require review. Tell your clinician about planned anesthesia or sedation. Seek urgent care for severe or persistent abdominal pain, serious allergic reactions, or other severe symptoms. Concentration and dosing-unit differences in compounded injections can cause dosing errors. Confirm the exact instructions and measuring device with the prescriber and dispensing pharmacy.
A licensed clinician determines eligibility, whether a video or in-person visit is needed, the treatment plan, and appropriate follow-up under state law. Prescription approval is not guaranteed. Any prescribed medication must be dispensed by a licensed pharmacy. Follow only the prescriber’s and pharmacy’s instructions for the specific formulation and concentration.
Compounded medications are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Eligibility, appropriateness, and lawful availability require individual clinician and licensed-pharmacy review.